PRECISION BIOSCIENCES INC
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Financial Statements
The following documents are included on pages F-1 through F-32 attached hereto and are filed as part of this Annual Report on Form 10-K.
(a)(2) Financial Statement Schedules
All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.
(a)(3) Exhibits
The following is a list of exhibits filed, furnished or incorporated by reference as part of this Annual Report on Form 10-K.
Exhibit Index
| ExhibitNumber | Description | Form | File No. | Exhibit | FilingDate | FiledHerewith |
|---|---|---|---|---|---|---|
| 2.1†† | Asset Purchase Agreement, dated as of August 15, 2023, by and among Precision BioSciences, Inc., Imugene (USA) Inc. and Imugene Limited. | 8-K/A | 001‑38841 | 2.1 | 8/21/2023 | |
| 3.1 | Amended and Restated Certificate of Incorporation of Precision BioSciences, Inc. | 8‑K | 001-38841 | 3.1 | 4/1/2019 | |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of Precision BioSciences, Inc. | 8-K | 001-38841 | 3.1 | 2/13/2024 | |
| 3.3 | Amended and Restated Bylaws of Precision BioSciences, Inc. | 8-K | 001‑38841 | 3.1 | 12/22/2023 | |
| 4.1 | Specimen Common Stock Certificate. | S‑1/A | 333‑230034 | 4.1 | 3/18/2019 | |
| 4.2 | Form of Indenture. | S-3 | 333-272540 | 4.3 | 6/9/2023 | |
| 4.3 | Form of Warrant. | 8-K | 001-38841 | 4.1 | 3/1/2024 | |
| 4.4 | Description of Registrant’s Securities. | * | ||||
| 10.1 | Amended and Restated Loan and Security Agreement, entered into as of July 31, 2024, by and between Banc of California and Precision BioSciences, Inc. | 10-Q | 001-38841 | 10.7 | 8/01/2024 | |
| 10.2††† | License Agreement, dated January 7, 2024, by and among TG Therapeutics, Inc., TG Cell Therapy, Inc. and Precision BioSciences, Inc. | 10-K | 001-38841 | 10.2 | 3/27/2024 | |
| 10.3††† | License Agreement, effective as of August 15, 2023 by and between Precision BioSciences, Inc. and Imugene (USA) Inc. | 8-K/A | 001-38841 | 10.1 | 8/21/2023 | |
| 10.4†† | Program Purchase Agreement, dated April 9, 2021, by and among Les Laboratoires Servier, Institut de Recherches Internationales Servier, and Precision BioSciences, Inc. | 10-Q | 001-38841 | 10.1 | 5/13/2021 | |
| 10.5††† | Amended and Restated Development and License Agreement, dated June 30, 2023, by and between Prevail Therapeutics, Inc. and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.1 | 7/6/2023 | |
| 10.6††† | Collaboration and License Agreement, dated June 14, 2022, by and between Precision BioSciences, Inc. and Novartis Pharma AG. | 8-K | 001-38841 | 10.1 | 6/21/2022 | |
| 10.7† | License Agreement, dated April 17, 2006, as amended, by and between Duke University and Precision BioSciences, Inc. | S‑1 | 333‑230034 | 10.2 | 3/1/2019 | |
| 10.8† | Patent Cross‑License Agreement, dated January 23, 2014, by and between Cellectis SA and Precision BioSciences, Inc. | S‑1 | 333‑230034 | 10.3 | 3/1/2019 | |
| 10.9 | Lease Agreement, dated April 5, 2010, as amended, by and between Precision BioSciences, Inc. and Venable Tenant, LLC. | 10-K | 001-38841 | 10.12 | 3/27/2024 | |
| 10.10# | 2006 Stock Incentive Plan, as amended, and form of award agreements thereunder. | S‑1 | 333‑230034 | 10.8 | 3/1/2019 | |
| 10.11# | 2015 Stock Incentive Plan, as amended, and form of award agreements thereunder. | S‑1 | 333‑230034 | 10.9 | 3/1/2019 | |
| 10.12# | 2019 Incentive Award Plan (As Amended and Restated Effective June 4, 2024) and forms of award agreements thereunder. | 8-K | 001-38841 | 10.1 | 6/10/2024 | |
| 10.13# | 2019 Employee Stock Purchase Plan. | S‑1/A | 333‑230034 | 10.11 | 3/18/2019 | |
| 10.14# | 2021 Employment Inducement Incentive Award Plan and forms of award agreements thereunder. | S-8 | 333-259369 | 99.3 | 9/7/2021 | |
| ExhibitNumber | Description | Form | File No. | Exhibit | FilingDate | FiledHerewith |
|---|---|---|---|---|---|---|
| 10.15# | Amendment, effective as of August 22, 2022, to the 2021 Employment Inducement Incentive Award Plan. | S-8 | 333-267079 | 99.4 | 8/26/2022 | |
| 10.16# | Amendment, effective as of June 4, 2024, to the 2021 Employment Inducement Incentive Award Plan. | S-8 | 333-280618 | 99.4 | 7/1/2024 | |
| 10.17# | Executive Employment Agreement, dated January 22, 2024, by and between Michael Amoroso and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.1 | 1/23/2024 | |
| 10.18# | Executive Employment Agreement, dated January 22, 2024, by and between Alex Kelly and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.2 | 1/23/2024 | |
| 10.19# | Executive Employment Agreement, dated January 22, 2024, by and between Dario Scimeca and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.3 | 1/23/2024 | |
| 10.20# | Executive Employment Agreement, dated January 22, 2024, by and between Jeff Smith and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.4 | 1/23/2024 | |
| 10.21# | Form of Indemnification Agreement between Precision BioSciences, Inc. and its directors and officers. | S‑1A | 333‑230034 | 10.17 | 3/18/2019 | |
| 10.22# | Non‑Employee Director Compensation Plan (as amended). | 10-Q | 001-38841 | 10.1 | 5/9/2023 | |
| 10.23# | Consulting Agreement between Precision BioSciences, Inc. and Dr. Alan List, dated September 13, 2024 | 10-Q | 001-38841 | 10.1 | 11/04/2024 | |
| 19.1 | Precision BioSciences, Inc. Insider Trading Compliance Policy | * | ||||
| 21.1 | Subsidiaries of Precision BioSciences, Inc. | * | ||||
| 23.1 | Consent of Deloitte & Touche LLP. | * | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | * | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | * | ||||
| 32.1 | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ** | ||||
| 32.2 | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ** | ||||
| 97 | Clawback policy | 10-K | 001-38841 | 97 | 3/27/2024 | |
| 101.INS | XBRL Instance Document | * | ||||
| 101.SCH | XBRL Taxonomy Extension Schema Document | * | ||||
| 104 | Cover Page Interactive Data File (as formatted as Inline XBRL and contained in Exhibit 101) | * | ||||
- Filed herewith
** Furnished herewith
†Confidential treatment of certain provisions has been granted by the SEC pursuant to Rule 406 under the Securities Act of 1933, as amended.
††Portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K.
†††Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
#Denotes a management contract or compensatory plan or arrangement
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.